TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02668419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulator
Description: Quadriceps and calf muscles of both legs were simultaneously stimulated using self adhesive surface rectangular electrodes. During all session period, the patients were maintained in the supine Fowler 45º position. Stimulation parameters were set up as follows: biphasic current of 40 Hz, 400-µs pulse duration, mode on-time 10s and off-time 20s and maximal amplitude of 60 mA. The stimulation intensity was progressively increased according to the patient tolerance until a muscular contraction was observed. Stimulation was performed twice a day; the session duration was 60 min.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy Session
Description: each session consisted of breathing exercises and global active exercises of the upper and lower limbs in bed. The treatment was applied twice a day during the hospitalization period. The protocol was interrupted if the patient had signs or symptoms suggestive of poor tolerance to exercise: 1) cyanosis, pallor, dizziness, nausea or pre-syncope; 2) chest pain; 3) bradycardia; 4) a drop in systolic blood pressure \>15 mmHg in comparison to baseline; 5) an excessive rise in systolic blood pressure defined as \>200 mmHg; 6) a rise in diastolic blood pressure during exercise \>110 mmHg; 7) fatigue rated ≥6/10 on the perceived exertion Borg scale (PEB); and/or 8) electrocardiographic signs of cardiac ischemia or ventricular arrhythmias.
Study: NCT04078399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine combined with interferon preemptive treatment
Description: Azacitidine combined with interferon preemptive therapy for prevention and treatment of recurrence of allogeneic transplantation of myeloid tumors (AML/MDS/MPN) in the blood system
Study: NCT04477122

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy and extracorporeal radial shock waves therapy
Description: 25 minutes of manual therapy, 5 minutes of temporomandibular joint mobilization and 3 minutes of extracorporeal radial shock waves therapy (real or placebo)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Manual therapy and extracorporeal radial shock waves therapy
Description: 25 minutes of manual therapy, 5 minutes of temporomandibular joint mobilization and 3 minutes of extracorporeal radial shock waves therapy (real or placebo)
Study: NCT02940964

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Count on me Singapore (COMS) CPR
Description: Using the song as a mental metronome to guide CPR.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard CPR
Description: Standard CPR with one-and-two-and-three.... counting
Study: NCT03542552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Patients received intravenous 6 g bolus MgSO4 20% followed by a 2 g/h infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: received oral nifedipine 10 mg every 20 minutes for three doses, followed by 10 mg orally every 6 hours
Study: NCT02621333

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CIK
Description: platinum combined doublets: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/m2，D1-3 or carboplatin AUC=5, D1. After 3 or 4 days of chemotherapy, about 5×109 autologous cytokine-induced killer cells are transfused into the vein of patients in one hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: platinum combined doublets: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/m2，D1-3 or carboplatin AUC=5, D1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: platinum combined doublets: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/m2，D1-3 or carboplatin AUC=5, D1.
Study: NCT00278824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matrix Transdermal Fentanyl/CHADD Drug Delivery System
Description: Patch applied every 3 days for 15 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Placebo patch applied every 3 days for 15 days
Study: NCT03968510

Intervention type: PROCEDURE
Intervention: parathyroidectomy
Description: routine parathyroidectomy will be done for the treatment of adenoma
Study: NCT04396457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Human PD-1 Monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Antineoplastic antimetabolite
Study: NCT02197962

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Radial shockwaves
Description: Patients will receive 2,000 impulses of extracorporeal radial shockwaves or per week, with pressure of 2.5bar to 4.0bar, at the frequency of 8Hz. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Radial Shockwaves
Description: Patients will receive 2,000 impulses of placebo extracorporeal radial shockwaves per week, without any pressure, therefore no energy will be applied, at the frequency of 8Hz. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.
Study: NCT03490344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: * Cycles 1 and 2: Daratumumab 16mg/kg weekly per cycle (28 days) as intravenous infusion (total duration: 8 weeks)~* Cycles 3-6: Daratumumab 16mg/kg once every 2 weeks per cycle (28 days) as intravenous infusion (total duration: 16 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide maintenance therapy to be administered as standard treatment to all participants. This is administered as 5-15 mg daily 21-28/28 day cycle.
Study: NCT02875288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal bupivicaine
Description: 1. The intervention that is being tested and who will perform the procedures; Two general surgeons will perform the procedure with either liposomal or plain bupivacaine.~2. The treatment procedures or regimens; The treatment procedure is direct, surgical site infiltration with either liposomal or plain bupivacaine.~3. Dosage level and justification; Liposomal Bupivacaine: 266 mg/20 mL liposomal bupivacaine diluted to 30 mL Plain Bupivacaine: 30 mL of 0.5% plain bupivacaine~4. Route of drug administration; Surgical site infiltration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liposomal bupivicaine
Description: 1. The intervention that is being tested and who will perform the procedures; Two general surgeons will perform the procedure with either liposomal or plain bupivacaine.~2. The treatment procedures or regimens; The treatment procedure is direct, surgical site infiltration with either liposomal or plain bupivacaine.~3. Dosage level and justification; Liposomal Bupivacaine: 266 mg/20 mL liposomal bupivacaine diluted to 30 mL Plain Bupivacaine: 30 mL of 0.5% plain bupivacaine~4. Route of drug administration; Surgical site infiltration
Study: NCT03429075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin + Placebo
Description: Multiple dosing days psilocybin vs 6 weeks of daily placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin + Escitalopram
Description: Multiple dosing days psilocybin vs 6 weeks of daily escitalopram
Study: NCT02845869

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THOR Laser LX2 System
Description: Treatment session will take up to 25 minutes and will include stimulation of local lymph nodes and soft tissue, de-activation of trigger points, and eliciting analgesia.
Study: NCT04408794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant (BHV-3500)
Description: 10 mg IN up to 8 times per month, up to 1 year
Study: NCT01424761

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Description: Coenzyme Q10 300 mg/d (150 mg/bid)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo :starch
Study: NCT01778010

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Modafinil 0 mg
Description: Modafinil (0 mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg
Description: Modafinil (200 mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg
Description: Modafinil (400 mg/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocaine 0 mg
Description: Cocaine (0 mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine 0 mg
Description: Cocaine (0 mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine 0 mg
Description: Cocaine (0 mg/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocaine 12 mg
Description: Cocaine (12 mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine 12 mg
Description: Cocaine (12 mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine 12 mg
Description: Cocaine (12 mg/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocaine 25 mg
Description: Cocaine (25 mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine 25 mg
Description: Cocaine (25 mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine 25 mg
Description: Cocaine (25 mg/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocaine 50 mg
Description: Cocaine (50 mg/day)
Study: NCT04868903

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Half the subjects will be randomized to the low dose vitamin D therapy (400 IU/day), which will serve as the control group, and half to moderate (4,000 IU/day) or high (10,000 IU/day). Study participants will have the option between being randomized to the low versus moderate or the low versus high dose arms.
Study: NCT02595905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study: NCT03502785

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-5401
Description: INO-5401 (9 milligram \[mg\] dose IM): mixture of 3 synthetic plasmids that target Wilms' tumor gene-1 (WT1) antigen, prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT) antigen.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-5401
Description: INO-5401 (9 milligram \[mg\] dose IM): mixture of 3 synthetic plasmids that target Wilms' tumor gene-1 (WT1) antigen, prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT) antigen.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-9012
Description: INO-9012 (1 mg dose IM): A synthetic plasmid that expresses human interleukin-12 (IL-12).~INO-5401 + INO-9012 will be administered IM followed by EP with CELLECTRA™ 2000 device every 3 weeks for 4 doses then every 6 weeks for 6 additional doses, thereafter every 12 weeks until confirmed disease progression, unacceptable toxicity, or deemed intolerable by the investigator.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-9012
Description: INO-9012 (1 mg dose IM): A synthetic plasmid that expresses human interleukin-12 (IL-12).~INO-5401 + INO-9012 will be administered IM followed by EP with CELLECTRA™ 2000 device every 3 weeks for 4 doses then every 6 weeks for 6 additional doses, thereafter every 12 weeks until confirmed disease progression, unacceptable toxicity, or deemed intolerable by the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered by intravenous (IV) infusion every 3 weeks until confirmed disease progression, unacceptable toxicity, or deemed intolerable by the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered by intravenous (IV) infusion every 3 weeks until confirmed disease progression, unacceptable toxicity, or deemed intolerable by the investigator.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA™ 2000
Description: IM injection of INO-5401 and INO-9012 is followed by EP with the CELLECTRA™ 2000 device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA™ 2000
Description: IM injection of INO-5401 and INO-9012 is followed by EP with the CELLECTRA™ 2000 device.
Study: NCT01778010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine 50 mg
Description: Cocaine (50 mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine 50 mg
Description: Cocaine (50 mg/day)
Study: NCT04178850

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB242
Description: GB242: Dosing of 3 mg/kg, intravenous drip, to be completed over 120 minutes, dosing at weeks 0, 2, 6, 14 and 22, a total of 5 doses; MTX:Dosage and administration at enrollment are maintained (10\~15mg/week), oral administration, a total of 30 doses; Folic acid: 5-10mg/week, oral administration, a total of 30 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Infliximab: Dosing of 3 mg/kg, intravenous drip, to be completed over 120 minutes, dosing at weeks 0, 2, 6, 14 and 22, a total of 5 doses; MTX:Dosage and administration at enrollment are maintained (10\~15mg/week), oral administration, a total of 30 doses; Folic acid: 5-10mg/week, oral administration, a total of 30 doses
Study: NCT02896010

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sweetch App + DBWS
Description: Usual care for prediabetes management, Sweetch app, weight monitoring via digital body weight scale (DBWS).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sweetch App Alone
Description: Usual care for prediabetes management, Sweetch app alone.
Study: NCT02837991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-014
Study: NCT04180280

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral self-regulation Phone counseling to improve HIV care
Description: Participants receive 5 sessions of behavioral counseling to improve HIV care. Counseling is delivered using phone calls by a trained adherence and care engagement counselor.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral self-regulation Office counseling to improve HIV care
Description: Participants receive 5 sessions of behavioral counseling to improve HIV care. Counseling is delivered in clinical care offices s by a trained adherence and care
Study: NCT04564053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNA043
Description: Single intra-articular injection on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single intra-articular injection on Day 1
Study: NCT02845869

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Therapy
Description: The therapeutic light will be turned off but the system will produce similar noises and mild heat.
Study: NCT04564053

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intra-articular injection on Day 1
Study: NCT03144453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex Injectable Product
Description: Patients receive sugammadex at the end of the surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine, Atropine
Description: Patients receive neostigmine+atropine at the end of the surgery
Study: NCT02744794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermal Cooling System
Description: Treatment with cryotherapy.
Study: NCT04030845

Intervention type: PROCEDURE
Intervention: breast reconstruction
Description: The breast reconstruction mainly included autologous tissue flaps (latissimus dorsi myocutaneous flaps, pedicled tansverse rectus abdominis myocutaneous flaps, free transverse rectus abdominis musculocutaneous flaps, deep inferior epigastric artery perforator flaps, etc.), implant based breast reconstruction, autologous flaps combined with implant reconstruction, fat graft, etc.
Study: NCT01101074

Intervention type: OTHER
Intervention: This is non-intervention observational study
Description: This is non-intervention observational study

Intervention type: OTHER
Intervention: This is non-intervention observational study
Description: This is non-intervention observational study

Intervention type: OTHER
Intervention: This is non-intervention observational study
Description: This is non-intervention observational study

Intervention type: OTHER
Intervention: This is non-intervention observational study
Description: This is non-intervention observational study

Intervention type: OTHER
Intervention: This is non-intervention observational study
Description: This is non-intervention observational study

Intervention type: OTHER
Intervention: This is non-intervention observational study
Description: This is non-intervention observational study
Study: NCT00837330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab 0.5 or 0.3 mg/0.05 cc
Description: ranibizumab 0.5 or 0.3 mg/0.05 cc administered intraocularly on a monthly basis for 3 months, followed by monthly examination with the option of further ranibizumab treatment or other therapies at the discretion of the treating physician

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab 0.5 or 0.3 mg/0.05 cc
Description: ranibizumab 0.5 or 0.3 mg/0.05 cc administered intraocularly on a monthly basis for 3 months, followed by monthly examination with the option of further ranibizumab treatment or other therapies at the discretion of the treating physician
Study: NCT02919293

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine (adjuvant-free)
Description: 30μg /dose, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine(adjuvant)
Description: 0.5ml /dose, Intramuscular
Study: NCT02456623

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Home-based session targeting the parent
Study: NCT03390491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OnTrack>TheGame (OTG)
Description: OTG clients will be informed that the game can be played on a computer or a tablet and the time estimate for completing the game is approximately 5-8 hours. OnTrack\>The Game offers players the opportunity to immerse in a fictional neighborhood that centers around four domains for supportive recovery as defined by SAMHSA: health, home, purpose and community. The player interacts with other game characters including new acquaintances, friends/peers, a family member, and a treatment team, allowing the player to practice social and communication skills, while fostering personal relationships and building a support network. Additionally, the game provides players with helpful resources including psychoeducation materials and videos of real people who have experienced a first episode of psychosis, sharing their stories of hope and recovery. As a whole, the game provides a safe environment to promote goal attainment and recovery.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Recovery Videos (RV)
Description: As described, RV clients will have access to a website that includes recovery videos and static psychoeducation materials. In this condition, mental health providers will also ask about possible reactions to viewing the recovery videos and information on the website.
Study: NCT01113957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-888
Description: Arm-A subjects will be given ABT-888 on Days 1 -7 every 28 days orally
Study: NCT02456623

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Attention condition with newsletters and support phone calls
Study: NCT00513344

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dark Chocolate
Description: 1 portion
Study: NCT01113957

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated liposomal doxorubicin
Description: Arm B subjects randomized to pegylated liposomal doxorubicin on Day 1, every 28 days intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Arm A subjects will be given temozolomide on days 1-5 every 28 days orally with ABT-888
Study: NCT03432689

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Single-pulse transcranial magnetic stimulation and theta-burst stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Single-pulse transcranial magnetic stimulation and theta-burst stimulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cycloserine
Description: Cycloserine 100mg
Study: NCT04030845

Intervention type: PROCEDURE
Intervention: oncoplastic breast-conserving surgery
Description: The oncoplastic breast-conserving surgery were mainly those surgeries using volume displacement or volume replacement techniques.
Study: NCT03432689

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo capsule matched to cycloserine capsule
Study: NCT03964129

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Avance Nerve Graft with Autologous BMAC
Description: The Avance Nerve Graft will be inserted in the area of nerve injury. Between 40 to 60 ml of Bone Marrow Aspirate from the anterior or posterior iliac crest of the pelvis will be harvested. Using SmartPrep centrifuge and 60 ml BMAC kit, 7 to 10 ml of final BMAC will be obtained. Of the 7 to 10 ml of final BMAC that is yielded, half (3.5 to 5 ml) of the final concentrate, will be injected on top of the Avance Nerve Graft following coaptation. The second half (3.5 to 5 ml) of the final concentrate will be inserted into a sterile tube containing culture media and shipped overnight to Cleveland Clinic Lerner Research Institute for cell processing and colony assay to confirm that the BMAC indeed contains autologous bone marrow stem cells.